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E-mail address: oohashi@gifu-u.ac.jp (K. Oh-hashi)In this study, we found that Cysteine-rich with EGF-like domains 2 (CRELD2), a novel endoplasmic
reticulum stress-inducible protein, is not only localized in the ER-Golgi apparatus but also sponta-
neously secreted. Deletion of four C-terminal amino acids from mouse CRELD2 or addition of tag-
peptides to its C-terminus dramatically enhanced CRELD2 secretion. Intra- and extra-cellular
CRELD2 is differentially glycosylated and its spontaneous secretion was signiﬁcantly prevented by
overexpression of a dominant negative mutant Sar1 and treatment with brefeldin A. Overexpression
of wild-type GRP78 remarkably enhanced the secretion of wild-type but not mutant CRELD2. Our
results demonstrate both that CRELD2 is a novel secretory glycoprotein regulated by Sar1 and
GRP78 and that the C-terminal of CRELD2 plays a crucial role in its secretion.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The endoplasmic reticulum (ER) is an organelle that plays a key
role in folding and modifying newly synthesized transmembrane
and secretory proteins [1,2]. Some pathophysiological conditions
are reported to disrupt ER function by accumulating unfolded pro-
teins [3,4]. Abnormal function due to their accumulation is referred
to as ER stress, and various stress response phenomena are medi-
ated by three resident ER stress sensors: PERK [5], IRE [6] and
ATF6 [7]. Many genes have been identiﬁed as ER stress-inducible
ones, and the stress sensors were demonstrated to regulate their
expression [5–10].
Using microarray analysis of thapsigargin-inducible genes in
Neuro2a cells, we recently identiﬁed CRELD2 gene as a novel ER
stress-inducible gene [11]. In addition, ATF6 has been found to pos-
itively regulate the transcription of the CRELD2 gene through the
well-conserved ER stress response element (ERSE) at the proximal
region of the mouse CRELD2 promoter.
CRELD2 was ﬁrst identiﬁed as a homologue to CRELD1, which is
one of the atrioventricular septal defects (AVSD)-related genes
[12–14]. CRELD2 has been reported to mediate the intracellular
trafﬁcking of acetylcholine receptor a4 and b2 subunits [15,16].
We previously reported that CRELD2 is an approximately 60-kDa
glycoprotein that predominantly localizes to the ER and Golgi
apparatus [11]. However, the molecular features of CRELD2 protein
are poorly understood.chemical Societies. Published by E
.In this study, we ﬁrst characterize that CRELD2 is a novel secre-
tory glycoprotein and show that modiﬁcation of its C-terminal re-
gion enhances its secretion. In addition, two factors, GRP78 [17]
and Sar1 [18], are found to regulate the secretion of wild-type
CRELD2. These results suggest that CRELD2 might act as a multi-
functional factor both in the ER-Golgi apparatus and in the extra-
cellular space under normal and pathophysiological conditions.
2. Materials and methods
2.1. Materials
Tunicamycin (Tm) and brefeldin A (BFA) were purchased from
Sigma. Antibodies against Myc (9E10) and GRP78 were obtained
from Santa Cruz Biotechnology. An antibody against CRELD2 was
purchased from R&D Systems. Monoclonal Antibodies against hu-
man calnexin or human GM130 were obtained fromMBL. Endogly-
cosidase H (Endo H) and N-Glycosidase F (N-Gly) were purchased
from New England Biolabs and Roche Biochemicals, respectively.
2.2. Construction of plasmids
For preparation of mouse CRELD2 and GRP78 expression con-
structs, full-length mouse CRELD2 and GRP78 cDNAs were obtained
from DNAFORM. Each type of Myc/His-tagged mouse CRELD2 gene
was ampliﬁed by PCR and then cloned into the pcDNA3.1/myc-His
vector (FL-, D1 (1–287 aa)- and D2 (1–195 aa)-MH). Hemaggluti-
nin (FL-HA)-tagged and Flag-tagged CRELD2 (DN (28–350 aa)-
MH) were also prepared by PCR and cloned into the pcDNA3.1
vector and pFlag-CMV vector, respectively. Mouse wild-typelsevier B.V. All rights reserved.
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Fig. 1. Deletion of the C-terminal region of CRELD2 causes aberrant secretion. (A)
Comparison of amino acid sequences of CRELD2 at the C-terminus among various
species. (B) Four conserved C-terminal amino acids in various ER-resident proteins.
(C) Schematic structure of mouse CRELD2 expression vectors used in this study. (D)
Twenty-four hours after transfection of the indicated type of CRELD2 or an empty
vector (mock) into HEK293 cells, the culture medium was replaced with serum free
DMEM and the cells were incubated for an additional 18 h. The amount of CRELD2
in each lysate or in the culture medium was determined by western blotting, as
described in Section 2. SP indicates a signal sequence at the N-terminus. Open and
hatched boxes represent an EGF-like domain and furin-like repeats, respectively.
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(KDEL) (DGRP78) genes were also ampliﬁed by PCR using mouse
GRP78 cDNA and cloned into the pcDNA3.1 vector. HA-tagged
Sar1 construct (H79G) were kindly provided by Dr. Wei Liu and
Dr. Jennifer Lippincott-Schwartz [18].
2.3. Cell culture and treatment
COS7 cells and HEK293 cells were maintained in Dulbecco’s
Modiﬁed Eagle minimum essential Medium (DMEM) containing
8% fetal bovine serum. Transfection of each construct used in this
study was performed using Lipofectamine-Plus reagent (Invitro-
gen) according to the manufacturer’s instructions. Twenty-four
hours after transfection, culture medium was changed with fresh
DMEM and the cells were incubated for the indicated time. To de-
tect expression of Myc/His-tagged CRELD2 or other types of
CRELD2 in culture medium, the cells were incubated in the pres-
ence or absence of serum, respectively. To evaluate the effects of
Tm (2 lg/ml) or BFA (5 lg/ml) on CRELD2 processing and secre-
tion, each reagent was added into the culture medium when cul-
ture medium was changed with fresh DMEM.
2.4. Western blotting analysis
Cells were lysed with homogenate butter [20 mM Tris–HCl (pH
8.0) containing 137 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Triton
X-100, 1 mM PMSF, 10 lg/ml leupeptin, 10 lg/ml pepstatin A].
After protein concentration was determined, each cell lysate was
dissolved in sodium dodecyl sulfate (SDS)–Laemmli sample buffer
[62.5 mM Tris–HCl (pH 6.8), 2% SDS and 10% glycerol]. For detec-
tion of every type of CRELD2 in culture medium, an aliquot of
CRELD2-containing culture medium was concentrated using
Microcon (Millipore) or dried by a vacuum evaporator, and resus-
pended with SDS–Laemmli sample buffer. To detect Myc/His-
tagged CRELD2 (CRELD2-MH) in culture medium, CRELD2-MH
was concentrated by incubation with Ni-conjugated Sepharose
(GE Healthcare Bioscience) at 4 C for 2 h. After brief centrifuga-
tion, Ni-conjugated Sepharose was washed and resuspended with
SDS–Laemmli sample buffer. In each experiment, equal amounts
of each sample from lysates and culture medium were separated
on 8.0% or 10.0% SDS–polyacrylamide electrophoresis gels, trans-
ferred onto polyvinylidene diﬂuoride (PVDF) membrane (GE
Healthcare Bioscience) and identiﬁed using primary antibodies
against CRELD2, Myc-epitope or GRP78.
2.5. Fluorescent immunocytochemistry
COS7 cells expressing each type of CRELD2 on glass coverslips
were ﬁxed with PBS containing 4% paraformaldehyde for 10 min
as described previously [19]. For the detection of Myc-tagged
CRELD2 or untagged-CRELD2, ﬁxed cells were permeabilized with
PBS containing 0.2% Triton X-100 for 3 min. The coverslips were
then incubated with an anti-Myc monoclonal antibody or an
anti-CRELD2 polyclonal antibody for 1 h at room temperature.
After washing, coverslips were incubated with ﬂuorescein isothio-
cyanate (FITC)-conjugated anti-mouse IgG or anti-goat IgG as a
secondary antibody, for anti-Myc and anti-CRELD2, respectively.
Cell nuclei were stained with Hoechst 33823. To characterize the
subcellular localization of CRELD2 more precisely, cells expressing
the indicated types of CRELD2 were stained with an anti-CRELD2
polyclonal antibody together with anti-calnexin or GM130 mono-
clonal antibody. For secondary antibodies, ﬂuorescein isothiocya-
nate (FITC)-conjugated anti-goat IgG and rhodamine-conjugated
anti-mouse IgG were used. In all cases, the cells were mounted
in Vectashield (Vector Labs) and observed by ﬂuorescence micros-
copy (KEYENCE).2.6. Endoglycosidase digestions
An aliquot of cell lysate or culture medium in SDS–Laemmli
sample buffer obtained from CRELD2-transfected cells was incu-
bated with either Endo H (250 U) or N-Gly (0.5 unit) for 12 h at
37 C, as described previously [20]. As a control, an equal amount
of the same cell lysate was incubated without enzyme. Each sam-
ple was then analyzed by Western blotting using antibodies
against CRELD2 or Myc-epitope, as described above.
3. Results and discussion
Previously, we identiﬁed the mouse CRELD2 gene as a novel ER
stress-inducible gene and observed that CRELD2-MH and EGFP-
tagged CRELD2 are predominantly localized in the perinuclear
region including the ER and Golgi apparatus [11]. CRELD2 was orig-
inally identiﬁed as a homolog of CRELD1 [12–14]. However,
CRELD2 does not contain any putative transmembrane regions
homologous to amino acid sequences of CRELD1. To characterize
the molecular features of CRELD2, we ﬁrst compared C-terminal
amino acid sequences of CRELD2 among various species. As shown
in Fig. 1A and B, four amino acids, (R/H)EDL, at the C-terminus of
CRELD2, were well conserved among the seven indicated species
Fig. 2. Intracellular localization and secretion of wild-type and mutant CRELD2. Twenty-four hours after transfection of the indicated constructs into COS7 cells, the culture
medium was replaced with fresh medium and the cells were incubated for an additional 18 h (A) or 8 h (B). The amount of CRELD2 in each lysate or culture medium was
determined by western blotting as described in Section 2. COS7 cells transiently expressing the indicated type of CRELD2 were ﬁxed and stained with anti-CRELD2 (C) or anti-
Myc monoclonal antibody (D), together with Hoechst 33258 (nuclear stain) as described in Section 2.
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Fig. 3. Subcellular locarization of wild-type and DC CRELD2. COS7 cells transiently expressing wild-type (A) and DC CRELD2 (B) were ﬁxed and stained with anti-CRELD2,
anti-calnexin, or anti-GM130 antibody as described in Section 2.
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proteins [21]. Therefore, we prepared several CRELD2 expression
constructs, which were modiﬁed at the N- and C-terminal regions
(Fig. 1C), and compared their biosynthesis, localization and secre-
tion. After HEK293 cells were transfected with wild-type (wt),
lacking REDL (DC), Myc/His-tagged (MH) or HA-tagged (FL-HA)
CRELD2, each type of CRELD2 was detected in the cells and in
the culture medium, but expression of CRELD2 in the mock cells
was not detected in the present condition (Fig. 1D). However, the
secretion of wtCRELD2 was remarkably lower than that of other
types of CRELD2, even though the cells expressing each CRELD2
were incubated for 18 h until harvested. We next transfected these
CRELD2 constructs into COS7 cells and detected the intracellular
localization of each protein molecule in addition to their
expression in both cells and culture medium. Consistent with the
expression observed in HEK293 cells, CRELD2 (DC) was morehighly secreted from the cells relative to wtCRELD2 (Fig. 2A). These
two types of CRELD2 were stained throughout the cells but their
staining in the perinuclear region was relatively intensive
(Fig. 2C). Similarly, each mutant CRELD2 lacking the C-terminal re-
gion (D1- and D2-MH) was secreted, as well as Myc/His-tagged
full-length CRELD2 (FL-MH), and the intracellular localization of
each modiﬁed protein was similar to that of wtCRELD2 (Fig. 2B
and D). In contrast, another mutant CRELD2 lacking the N-terminal
region with a putative signal peptide (DN-MH) was detected only
within the cells (Fig. 2B). The intracellular localization of CRELD2
(DN-MH) was quite different from that of other types of CRELD2,
and the DN-MH mutant was diffused in the cytoplasmic space
(Fig. 2D). These results implied that the N-terminus of CRELD2 is
essential for its translocation into the ER-Golgi apparatus, whereas
the deletion of its C-terminal region had no effect on their accumu-
lation in the perinuclear region. Then, we characterized each type
Fig. 4. Effects of Tm and BFA on the glycosylation and secretion of CRELD2. (A)
Twenty-four hours after transfection of wtCRELD2 or CRELD2-MH (FL-MH) into
HEK293 cells, the culture medium was replaced with fresh medium containing Tm
(5 lg/ml), BFA (5 lg/ml), or vehicle and the cells were incubated for an additional
12 h (wt) or 8 h (FL-MH). (B) Samples containing wtCRELD2 or CRELD2-MH in each
cell lysate and culture medium were treated with Endoglycosidase H (Endo H), N-
Glycosidase F (N-Gly) or vehicle. Expression of each type of CRELD2 was determined
by western blotting as described in Section 2.
Fig. 5. Co-expression of Sar1 (H79G) reduces CRELD2 secretion. Twenty-four hours
after transfection of wtCRELD2 or CRELD2-MH together with Sar1 (H79G) or empty
vector into HEK293 cells, the culture medium was replaced with fresh medium and
the cells were incubated for an additional 12 h (wt) or 4 h (FL-MH). The amount of
CRELD2 in each lysate or culture medium was determined by western blotting as
described in Section 2.
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GM130, a marker of ER or Golgi apparatus respectively. A shown
in Fig. 3, the intensive signal of wild-type or DC CRELD2 was par-
tially overlapped with that of GM130 in the perinuclear region.
Localizations of other CRELD2, FL-, D1- and D2-MH, also showed
the similar patterns in COS7 cells (Supplemental Fig. 1).
Next, we studied the effects of Tm, an inhibitor of protein gly-
cosylation, and BFA, a reagent disrupting the Golgi apparatus, on
glycosylation and secretion of CRELD2. The effects of Tm and
BFA on modiﬁcation and secretion of each type of CRELD2 were al-
most similar (Fig. 4A), though the duration of treatment of
wtCRELD2-transfected cells with Tm and BFA was different from
that of CRELD2-MH (FL-MH). The Tm treatment generated a lower
molecular size of CRELD2, which could be an unglycosylated form.
Interestingly, only a small amount of unglycosylated CRELD2 was
also detected in the culture medium. The glycosylation of wtC-
RELD2 was also conﬁrmed by treatment with two glycosidases,
Endo H, which removes mannose sugar moieties, and N-Gly, which
deglycosylates N-linked complex carbohydrates. The intracellular
wtCRELD2 was sensitive to both glycosidases, whereas the carbo-
hydrate motif of secreted wtCRELD2 was only deglycosylated by
N-Gly (Fig. 4B). The deglycosylation of CRELD2-MH with each gly-
cosidase also showed a similar pattern. Therefore, each type of
CRELD2 is glycosylated in a similar manner, despite considerably
different secretory efﬁciencies. These results furthermore imply
that only a small part of CRELD2 is secreted into extracellular
space followed by additional modiﬁcation of intracellular CRELD2,
but the greater part of CRELD2 retain intracellularly. On the other
hand, BFA almost completely prevented each type of CRELD2 from
the secretion (Fig. 4A). Taken together, these results suggest that
CRELD2 is partially secreted via the ER-Golgi apparatus route
and its glycosylation is not essential for the secretion.To reveal the molecular mechanism regulating the transport of
CRELD2 within the ER and Golgi apparatus, we focused on the
small GTPase Sar1, which is a critical component of COPII, essential
for an early step in vesicle budding and regulates vesicular trans-
port from the ER to the Golgi apparatus [18,22,23]. Overexpression
of Sar1 (H79G), which is the GTP-bound mutant and constitutive
active form, dampens the export of cargo from ER [18,23]. In this
study, co-transfection of Sar1 (H79G) with wtCRELD2 or CRELD2-
MH markedly reduced the CRELD2 secretion and increased the
accumulation of intracellular CRELD2 (Fig. 5). The effects of Sar1
(H79G) and BFA on CRELD2 secretion indicate that the COPII-
mediated transport from the ER to the Golgi apparatus is a main
pathway for CRELD2 secretion.
Finally, we studied the effects of GRP78 on the secretion of
CRELD2, as GRP78 has been reported to regulate the degradation,
transport and secretion of many kinds of proteins [24–28]. As
shown in Fig. 1B, GRP78 possesses the well-known ER-resident sig-
nal sequence at its C-terminus, KDEL. Therefore, we transfected
wild-type GRP78 (wtGRP78) or mutant GRP78 lacking the C-
terminal KDEL sequence (DGRP78), together with various types
of CRELD2 into HEK 293 cells (Fig. 6). Overexpression of wtGRP78
but not of DGRP78 remarkably increased wtCRELD2 secretion,
whereas the effect of wtGRP78 on DC CRELD2 secretion was negli-
gible when each band was quantiﬁed by NIH image. The secretion
of CRELD2-MH was hardly affected by either type of GRP78. On the
other hand, GRP78 in the culture medium was not detected in the
present condition. These results indicate that the elevated amount
of GRP78 would act as a positive regulator to facilitate the secre-
tion of CRELD2 under certain pathophysiological conditions.
Though further characterization of the intracellular transport,
modiﬁcation and secretion of CRELD2 under normal and patholog-
ical conditions are required, the excess GRP78 would mask the
interaction of CRELD2 with KDEL receptor to decrease its intracel-
lular retention and promote its secretion. The KDEL sequence in
GRP78 probably has higher afﬁnity toward the receptor than the
REDL sequence in CRELD2.
We previously demonstrated that CRELD2 is a novel ER stress-
inducible gene [11], which is transcriptionally regulated by ATF6
(one of the three major ER stress sensors, ATF6 [7–10], PERK
[5,8] and IRE1 [6,9]), but its molecular features and functions are
hardly characterized. Ortiz et al. reported that human CRELD2
(hCRELD2) impairs the membrane transport of acetylcholine
receptor a4/b2 [15]. They evaluated functions of two C-terminal
splicing variants of hCRELD2 (a and b) with respect to their inter-
action with acetylcholine receptor a4. The hCRELD2a gene is
Fig. 6. Overexpression of GRP78 potentiates wtCRELD2 secretion. Twenty-four
hours after transfection of wtCRELD2, CRELD2 (DC) or CRELD2 (FL-MH) together
with either wtGRP78, DGRP78 or empty vector (mock) into HEK293 cells, the
culture medium was replaced with fresh medium, and the cells were incubated for
the appropriate time (12 h for wt, 6 h for DC or 4 h for FL-MH). The amount of
CRELD2 in each lysate or culture medium was determined by western blotting as
described in Section 2.
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encoding REDL, whereas the C-terminal amino acids of hCRELD2b
are different from those of hCRELD2a. Furthermore, Ortiz et al.
showed that the WE domain (rich in tryptophan and glutamic
acids) of the common N-terminal region of hCRELD2 (25–130 aa)
and other regions of hCRELD2a (131–321 aa) and b (131–284 aa)
interact with the cytosolic domain of acetylcholine receptor a4
(331–381 aa) [15]. Therefore, the WE domain, EGF-like domain
and furin-like repeats form multiple binding regions to cytosolic
a4, but the C-terminal structure of CRELD2, which we character-
ized in this study, is unlikely to participate in the regulation of
membrane transport of acetylcholine receptor a4/b2. Very re-
cently, Hosur et al. [16] suggest that CRELD2 would have an antag-
onistic activity in nicotine-induced up-regulation of acetylcholine
receptor a4/b2. In their report, the induction of CRELD2 mRNA by
nicotine was not parallel with those of other ER stress-inducible
genes, GRP78 (HSPA5) [17,23–28] and HERPUD1 [29]. These results
suggest that CRELD2 is expected to function under ER stress-
unrelated conditions and that both the secreted and intracellular
CRELD2 are likely to contribute to some neuronal events via the
nicotinic signaling pathways.
Among the ER stress-inducible factors, arginine-rich, mutated in
early stage of tumors (Armet) [30,31] and nucleobindin 1 (NUCB1)
[32–34] are reported to be secretory proteins. Armet, also called
mesencephalic astrocyte-derived neurotrophic factor [35], is re-
ported to function as a cytoprotective factor against several stimuli
including neurotoxins [36], oxidative stress [37,38] and ER stress
[31] both in vivo and in vitro. The intracellular NUCB1 is preferen-
tially localized to the Golgi apparatus and interacts with S1P [34]
and Ga (i1 and i3) [39,40]. Tsukumo et al. [34] demonstrated that
the interaction of NUCB1 with S1P attenuates the cleavage of ATF6
and thus modulates its transcriptional activity. On the other hand,
the binding of NUCB1 to Ga (i1) was reported to regulate heterotri-
meric G protein trafﬁcking and G protein-coupled receptor-
mediated signal transduction pathways [40]. Like NUCB1 and
Armet, CRELD2 is expected to have multiple functions involving
the regulation of unidentiﬁed cellular processes both inside and
outside of cells. However, we have not observed any cytoprotective
features of CRELD2 in our study. Therefore, we believe that the
functions of CRELD2 are not directly associated with those of
Armet and NUCB1 despite the fact that the functions of the latter
are not fully understood.
Transgenic mice expressing mutant matrilin-3, a structural
protein of the cartilage extracellular matrix [41], and INS-1 cells
overexpressing mutant insulin 2 (C96Y) derived from the Akitamouse [42] are reported to express higher amounts of CRELD2
mRNA concomitantly with other known ER stress-inducible genes
(e.g., GRP78 and GADD153mRNA). However, Jariwala et al. [43] has
reported that CRELD2 is one of androgen target genes in prostate
cancer cells. Therefore, we believe that CRELD2 participates in both
ER stress-related and -unrelated pathophysiological conditions. In
this study, we ﬁrst demonstrated that a part of CRELD2 is secreted
as a glycoprotein, and characterized the roles of its N- and C-
terminal region in intracellular transport and secretion by overex-
pression of various types of CRELD2. By using cells producing
higher amount of CRELD2 protein intrinsically, further character-
ization of CRELD2’s role as a secretory factor as well as an
ER- and Golgi apparatus-resident protein would provide new in-
sights into the onset and progression of certain stress-related
diseases.
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